Aptevo Therapeutics Inc. (NASDAQ:APVO) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday.

Separately, Piper Jaffray Companies reiterated an “overweight” rating and set a $6.00 price target on shares of Aptevo Therapeutics in a report on Thursday, October 5th.

Aptevo Therapeutics (NASDAQ APVO) traded down 4.26% on Thursday, hitting $2.47. 219,016 shares of the stock were exchanged. The company’s 50-day moving average is $2.18 and its 200-day moving average is $2.18. Aptevo Therapeutics has a 52 week low of $1.15 and a 52 week high of $3.85. The company’s market cap is $52.90 million.

Aptevo Therapeutics (NASDAQ:APVO) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.08. The business had revenue of $10.76 million during the quarter. Aptevo Therapeutics had a negative return on equity of 64.80% and a negative net margin of 296.64%. On average, analysts predict that Aptevo Therapeutics will post $0.59 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/10/12/aptevo-therapeutics-inc-apvo-upgraded-at-valuengine.html.

Several institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP lifted its holdings in shares of Aptevo Therapeutics by 8.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,056,729 shares of the biotechnology company’s stock valued at $2,187,000 after buying an additional 78,109 shares during the last quarter. Precept Management LLC acquired a new stake in shares of Aptevo Therapeutics during the 2nd quarter valued at about $1,210,000. Legal & General Group Plc lifted its holdings in shares of Aptevo Therapeutics by 11,751.3% during the 2nd quarter. Legal & General Group Plc now owns 393,701 shares of the biotechnology company’s stock valued at $815,000 after buying an additional 390,379 shares during the last quarter. Finally, Spark Investment Management LLC lifted its holdings in shares of Aptevo Therapeutics by 167.4% during the 2nd quarter. Spark Investment Management LLC now owns 61,500 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 38,500 shares during the last quarter. Institutional investors and hedge funds own 39.16% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aptevo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.